These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 15322246

  • 1. Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist.
    Arlander SJ, Dong M, Ding XQ, Pinon DI, Miller LJ.
    Mol Pharmacol; 2004 Sep; 66(3):545-52. PubMed ID: 15322246
    [Abstract] [Full Text] [Related]

  • 2. Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer.
    Harikumar KG, Pinon DI, Wessels WS, Dawson ES, Lybrand TP, Prendergast FG, Miller LJ.
    Mol Pharmacol; 2004 Jan; 65(1):28-35. PubMed ID: 14722234
    [Abstract] [Full Text] [Related]

  • 3. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling.
    Dong M, Liu G, Pinon DI, Miller LJ.
    Biochemistry; 2005 May 03; 44(17):6693-700. PubMed ID: 15850403
    [Abstract] [Full Text] [Related]

  • 4. Differential spatial approximation between cholecystokinin residue 30 and receptor residues in active and inactive conformations.
    Dong M, Hadac EM, Pinon DI, Miller LJ.
    Mol Pharmacol; 2005 Jun 03; 67(6):1892-900. PubMed ID: 15774770
    [Abstract] [Full Text] [Related]

  • 5. Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor.
    Poirot SS, Escrieut C, Dufresne M, Martinez J, Bouisson M, Vaysse N, Fourmy D.
    Mol Pharmacol; 1994 Apr 03; 45(4):599-607. PubMed ID: 8183238
    [Abstract] [Full Text] [Related]

  • 6. Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.
    Gigoux V, Maigret B, Escrieut C, Silvente-Poirot S, Bouisson M, Fehrentz JA, Moroder L, Gully D, Martinez J, Vaysse N, Fourmy AD.
    Protein Sci; 1999 Nov 03; 8(11):2347-54. PubMed ID: 10595537
    [Abstract] [Full Text] [Related]

  • 7. A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely.
    Hadac EM, Ji Z, Pinon DI, Henne RM, Lybrand TP, Miller LJ.
    J Med Chem; 1999 Jun 17; 42(12):2105-11. PubMed ID: 10377216
    [Abstract] [Full Text] [Related]

  • 8. Direct identification of the agonist binding site in the human brain cholecystokininB receptor.
    Anders J, Blüggel M, Meyer HE, Kühne R, ter Laak AM, Kojro E, Fahrenholz F.
    Biochemistry; 1999 May 11; 38(19):6043-55. PubMed ID: 10320330
    [Abstract] [Full Text] [Related]

  • 9. Fluorescence characteristics of hydrophobic partial agonist probes of the cholecystokinin receptor.
    Harikumar KG, Pinon DI, Miller LJ.
    Biosci Rep; 2006 Apr 11; 26(2):89-100. PubMed ID: 16779661
    [Abstract] [Full Text] [Related]

  • 10. Structurally related peptide agonist, partial agonist, and antagonist occupy a similar binding pocket within the cholecystokinin receptor. Rapid analysis using fluorescent photoaffinity labeling probes and capillary electrophoresis.
    Dong M, Ding XQ, Pinon DI, Hadac EM, Oda RP, Landers JP, Miller LJ.
    J Biol Chem; 1999 Feb 19; 274(8):4778-85. PubMed ID: 9988716
    [Abstract] [Full Text] [Related]

  • 11. Molecular approximations between residues 21 and 23 of secretin and its receptor: development of a model for peptide docking with the amino terminus of the secretin receptor.
    Dong M, Lam PC, Gao F, Hosohata K, Pinon DI, Sexton PM, Abagyan R, Miller LJ.
    Mol Pharmacol; 2007 Aug 19; 72(2):280-90. PubMed ID: 17475809
    [Abstract] [Full Text] [Related]

  • 12. Differences in partial agonist action at cholecystokinin receptors of mouse and rat are dependent on parameters extrinsic to receptor structure: molecular cloning, expression and functional characterization of the mouse type A cholecystokinin receptor.
    Ghanekar D, Hadac EM, Holicky EL, Miller LJ.
    J Pharmacol Exp Ther; 1997 Sep 19; 282(3):1206-12. PubMed ID: 9316827
    [Abstract] [Full Text] [Related]

  • 13. Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling.
    Dong M, Lam PC, Pinon DI, Abagyan R, Miller LJ.
    Biochemistry; 2009 Jun 16; 48(23):5303-12. PubMed ID: 19441839
    [Abstract] [Full Text] [Related]

  • 14. Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites.
    Holleran BJ, Beaulieu ME, Proulx CD, Lavigne P, Escher E, Leduc R.
    Biochem J; 2007 Feb 15; 402(1):51-61. PubMed ID: 17064254
    [Abstract] [Full Text] [Related]

  • 15. Direct identification of a distinct site of interaction between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling.
    Ji Z, Hadac EM, Henne RM, Patel SA, Lybrand TP, Miller LJ.
    J Biol Chem; 1997 Sep 26; 272(39):24393-401. PubMed ID: 9305898
    [Abstract] [Full Text] [Related]

  • 16. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
    Boteju LW, Nikiforovich GV, Haskell-Luevano C, Fang SN, Zalewska T, Stropova D, Yamamura HI, Hruby VJ.
    J Med Chem; 1996 Sep 27; 39(20):4120-4. PubMed ID: 8831778
    [Abstract] [Full Text] [Related]

  • 17. Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor.
    Schmitz F, Pratt DS, Wu MJ, Kolakowski LF, Beinborn M, Kopin AS.
    Mol Pharmacol; 1996 Aug 27; 50(2):436-41. PubMed ID: 8700154
    [Abstract] [Full Text] [Related]

  • 18. Insights into the molecular basis of ligand binding by the cholecystokinin receptor.
    Miller LJ, Ding XQ.
    Pancreatology; 2001 Aug 27; 1(4):336-42. PubMed ID: 12120212
    [Abstract] [Full Text] [Related]

  • 19. Identification of a region of the N-terminal of the human CCKA receptor essential for the high affinity interaction with agonist CCK.
    Kennedy K, Escrieut C, Dufresne M, Clerc P, Vaysse N, Fourmy D.
    Biochem Biophys Res Commun; 1995 Aug 24; 213(3):845-52. PubMed ID: 7654246
    [Abstract] [Full Text] [Related]

  • 20. Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor.
    Ding XQ, Pinon DI, Furse KE, Lybrand TP, Miller LJ.
    Mol Pharmacol; 2002 May 24; 61(5):1041-52. PubMed ID: 11961122
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.